9 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding ... risk stratification ... #Diagnosis #Hematology ... #CHADS2 #CHADS2VASc ... #Anticoagulation
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
CHA2DS2VASc vs HAS-BLED ... and bleed risk ... on anticoagulation ... S Stroke 1 B Bleeding ... AFib #Diagnosis #Hematology
Venous Thromboembolism Treatment Algorithm
Branch points: 
Active bleeding?  Active malignancy? Provoked?

- Dr. Joseph Shatzel
@Clotmaster

#Management #VTE #DVT
Venous Thromboembolism ... Treatment Algorithm ... points: Active bleeding ... #Treatment #Hematology ... #Anticoagulation
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
Bleeding risk calculators ... - HAS-BLED (atrial ... of withholding anticoagulation ... Calculators #Anticoagulation ... #Factors #Hematology
Lower Extremity Venous Thrombosis - Management and Anatomy

Deep - Superficial - Active Bleeding

#LowerExtremity #Veins #Venous #Thrombosis
Lower Extremity Venous ... Superficial - Active Bleeding ... Deep #VTE #DVT #Hematology ... Management #Anatomy #Anticoagulation ... #Algorithm
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
patients at high risk ... of bleeding. ... risk during follow-up ... #Anticoagulation ... #Management #Hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... algorithm for the ... mass index; VTE = venous ... #Anticoagulation ... #Management #Hematology
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Longterm Venous ... PE - High Bleeding ... - Not High Bleeding ... #management #hematology ... #anticoagulation
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
• Treatment algorithms ... appropriate only for low risk ... patients with no CV risk ... Hydroxyurea + anticoagulation ... (if history of venous